// App-Quantinova.ai

529 : Development and validation of a new prognostic score on 4,646 patients with luminal-like breast cancer (BC) enrolled in 7 randomized prospective trials.

Researchers

Presenter

  • Caterina Fontanella

Principal Investigators

  • Lucia Del Mastro

  • Carsten Denkert

  • Sabino De Placido

  • Claus Hanusch

  • Francesco Cognetti

  • Jens Bodo Huober

  • Michele De Laurentiis

  • Christian Jackisch

  • Giancarlo Bisagni

  • Sherko Kummel

  • Ornella Garrone

  • Andreas Schneeweiss

  • Filippo Montemurro

  • Michael Untch

  • Claudia Bighin

  • Gunter Von Minckwitz

  • Sibylle Loibl

  • Fabio Puglisi

Medical Centers

  • University Hospital, Udine, Italy

  • German Breast Group (GBG), Neu-Isenbug, Germany

  • Department of Medical Oncology, U.O Sviluppo Terapie Innovative, IRCCS AOU IST-S.Martino, Genova, Italy

  • Charite Berlin, Institute of Pathology and German Cancer Consortium (DKTK), Berlin, Germany

  • University of Naples Federico II, Naples, Italy

  • Rotkreuzklinikum, Munich, Germany

  • Oncologia Medica, Istituto Nazionale Tumori Regina Elena, Roma, Italy

  • University of Ulm, Ulm, Germany

  • National Cancer Institute "Fondazione Pascale", Naples, Italy

  • Sana Klinikum Offenbach GmbH, Offenbach, Germany

  • Medical Oncology Unit, IRCCS-Arcispedale S. Maria Nuova, Reggio Emilia, Italy

  • Breast Unit, Kliniken Essen-Mitte, Essen, Germany

  • Medical Oncology, S.Croce & Carle Teaching Hospital, Cuneo, Italy

  • University Clinic Heidelberg, Heidelberg, Germany

  • Istituto di Candiolo, Fondazione del Piemonte per l'Oncologia, IRCCS, Candiolo, Italy

  • HELIOS Klinikum Berlin-Buch, Berlin, Germany

  • Department of Medical Oncology, U.O. Oncologia Medica 2, IRCCS AOU San Martino-IST, Genova, Italy

  • Department of Oncology, University Hospital of Udine, Udine, Italy

Locations

  • Germany

  • Italy

Companies

  • Sana Klinikum Offenb

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Epirubicin

  • taxane

  • Adrucil injection

Outcome

  • Positive

Study Design

  • Randomized

  • Prospective

  • Cohort

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved